Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Summary

This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.

Timeline

Start

2023-12-18

Primary completion

2025-09-08

Completion

2025-09-08

Outcome

Outcome not reported

Stopped (Business): “Limited resources and strategic priorities”

Drugs

Indications